Background: Borago officinalis and its derivatives are used in folk medicine to treat asthma because of its special effect on allergic disorders. It suppresses the tumor necrosis factor-alpha (TNF-alpha) and delivers gamma-linolenic acid. The objective of this clinical trial was to determine the effect of Borago officinalis on clinical and physiological findings in moderate persistent asthma. Materials and Methods: This prospective, randomized, double blind, placebocontrolled, clinical trial was conducted on patients aged 15-90 years with moderate asthma and forced expiratory volume in one second (FEV1) of 60-79% of predicted who presented to a sub-specialty clinic of pulmonary medicine. We randomly allocated subjects to receive either Borago extract (5 mL three times a day) or a matched placebo for one month. The primary outcome was the asthma control test (ACT) score and fractional exhaled nitric oxide (FENO) test. Secondary outcomes included clinical findings, spirometry, and sputum cytology including inflammatory cells. Results: Thirty-eight subjects with a mean age of 46.8±15.3 years and mean duration of asthma of 71±103 months were enrolled in our study. Cough, dyspnea, wheezing, nocturnal symptoms, and airway hyper-responsiveness reduced significantly in the Borago group after the treatment and ACT scores improved significantly (10.8±5.26 before and 15.4±5.12 after the trial). Flare up of asthma and emergency department visits in the Borago group also decreased significantly (3.6±2.33 to 2±1.86 flare ups per month and 0.62±0.9 to 0.05±0.23 for emergency department visits per month). Physiological parameters including spirometry, FENO, and sputum cytology including eosinophil and neutrophil did not change significantly. Conclusion: Borago improved the clinical findings of asthma, but it was not able to suppress the inflammation involved in asthma.
Borago officinalis and its Iranian species Echium amoenum contain several fatty acids including palmitic, linoleic, stearic, and γ-linolenic acids (1) . The flower of this plant is traditionally used in folk medicine as a bronchodilator (1) . Several mechanisms have been TANAFFOS described for this herbal drug; some of them are involved in asthma and allergic reactions. The anti-oxidative activity of herbal drugs was evaluated in Mediterranean herbal drugs, and Borago officinalis was found to contain the highest amount of sterols with anti-oxidative and antiinflammatory activities (2) . Thus, Borago officinalis has been effectively used for the topical treatment of atopic dermatitis (3) . The authors attributed the defective production of gamma-linolenic acid (GLA) to impaired activity of delta-6 desaturase enzyme that could be compensated by use of Borago extract rich in GLA. The benefit of Borago officinalis in treatment of inflammation was more than its local effect on atopic dermatitis. Its GLA content is able to suppress TNF-alpha via increasing cAMP and prostaglandin E levels in rheumatoid arthritis (4) .
TNF has been proven to increase in uncontrolled asthma (5) . Although TNF blockers (infliximab, etanercept and adalimumab) are not listed as standard therapy for asthma, they were used in experimental models of asthma and a small case series (6) , but their wide range of side effects and cost prevent their wide spread use for asthma (7) . Borago extract in this regard shows some benefits and by limiting its dosage we can control its side effects. A recent study showed its effect on arachidonic acid metabolism, which is very important in asthma (8) .
According to the promising results of experimental studies (7, 8) , use of Borago extract in clinical trials has been recommended. The aim of this study was to evaluate the effect of Borago extract on asthma.
MATERIALS AND METHODS

a. Participants:
Forty-two asthmatic patients older than 15 years were enrolled in this study. Two criteria were used to confirm the diagnosis of asthma: a) positive history of airway hyper-reactivity and history of recurrent episodes; and b) significant post-bronchodilator improvement (9 
b. Study design
The study was a prospective, phase 2b randomized, double blinded, placebo-controlled, parallel group clinical trial. The ethical committee of our university approved the study and it was registered in the Iranian clinical trial registry (IRCT201209302695N4).
c. Randomization and masking:
Computer generated random tables were used to randomly divide subjects into Borago extract and placebo groups. Assignment of subjects to each group was done by an independent assistant who was blinded to the study groups. unaware of the studied groups. Inhaled salbutamol was allowed to be used freely by patients as a reliever medication throughout the study.
f. Outcome variable measurement:
Primary end points were improvement in the score of the ACT questionnaire, which is a valid questionnaire for evaluating the activity of asthma (11) 
g. Sputum collection:
As the first step, we asked the subjects to expel sputum from their throat and try to expectorate sputum from their lungs. In case of no sputum, sputum induction was carried out by 5% saline inhalation in a compressor type nebulizer (CX3, Omron, Japan) according to the European Respiratory Society guidelines (13) .
h. Sputum processing:
Sputum preparation and decontamination of the saliva were performed by a liquid base commercial kit (E-prep Plus sol, Tehran, Iran). Two slides were prepared and stained by Papanicolaou stain for each subject and 300 nonsquamous cells were counted in each slide. The mean values of the results of the two slides were recoded. A predefined method for classification of inflammatory cells was used (10, 14) as follows: subjects with eosinophilic percentage more than 3% were classified as eosinophilic, neutrophilic percentage more than 76% as neutrophilic, both of them as mixed type and none of them as paucigranulocytic.
i. Time of outcome measurement:
The outcome variables were assessed at the time of the first visit and over the 30-day period of treatment.
Frequency of side effects to Borago extract and acute attacks including emergency department visits were evaluated at the final step of assessments.
j. Follow up:
Patients were followed up every two weeks by phone calls. Every subject who complained of coughing and unexpected side effects were excluded from the study and started on standard asthma treatments.
k. Statistical analysis
Sample size was calculated to detect 20% difference of primary outcome (ACT score) between Borago and placebo groups by means of 80% power and less than 5% error. 
RESULTS
a. Basic demographical findings
Forty-two subjects suffering from moderate stage asthma were recruited in this study, and 38 subjects ( were not significantly different. The differences in ACT scores between the two groups before the trial were not significant ( Table 2) . After the trial: Cough, dyspnea, wheezing, nocturnal symptoms and airway hyper-responsiveness significantly decreased in the Borago group (Table 1) . ACT scores also improved significantly (Table 2 ) and patients' reports of asthma acute attacks and emergency department visits decreased in the Borago group. Sputum production, symptoms aggravated by exercise, GERD, PND, spirometry parameters and FENO did not change significantly in the two groups (Tables 1 and 2 ).
c. Comparison of Borago with the placebo after the trial
Clinical findings including cough, dyspnea, sputum production, airway hyper-responsiveness, and GERD improved significantly in the Borago group compared to the placebo. ACT scores were also significantly higher in the Borago group, but other clinical findings including acute attack, spirometry parameters and FENO
were not significantly different with the placebo group (Tables 1 and 2 ).
Comparison of sputum inflammatory cells in Borago
and placebo groups before and after the trial showed no significant difference in proportion of inflammatory cells.
However, there were significant increments in lymphocyte percentage in the Borago group after the trial compared to lymphocyte in the Borago group before the trial and placebo group after the trial (Figure 1 ). Neutrophil count decreased in the Borago group after the trial, although it was not significant (Figure 1 ). Eosinophils as the most important inflammatory cells were higher in the Borago group (3.2±1.4%) than the placebo group (2.6±2.7%), but this difference was not significant.
Frequency of macrophages was in the range of 6.5-8%, which did not change after the trial in both groups. 
CONCLUSION
In conclusion, it was shown that temporary relief of asthma symptoms was achieved in symptomatic asthmatics who used Borago extract, and so it can be prescribed for asthma as an adjunct for patients who desire herbal drug treatment alternatives. Future studies about the mechanisms of action of Borago extract involved in asthma relief are recommended especially regarding the mechanism related to gamma-linolenic acid.
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